- Home
- BVFL vs PROK Comparison
BVFL vs PROK Comparison
Compare BVFL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- PROK
- Stock Information
- Founded
- BVFL 1873
- PROK 2015
- Country
- BVFL United States
- PROK United States
- Employees
- BVFL N/A
- PROK N/A
- Industry
- BVFL Savings Institutions
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BVFL Finance
- PROK Health Care
- Exchange
- BVFL Nasdaq
- PROK Nasdaq
- Market Cap
- BVFL 150.2M
- PROK 85.5M
- IPO Year
- BVFL N/A
- PROK N/A
- Fundamental
- Price
- BVFL $16.05
- PROK $7.00
- Analyst Decision
- BVFL
- PROK Hold
- Analyst Count
- BVFL 0
- PROK 3
- Target Price
- BVFL N/A
- PROK $3.50
- AVG Volume (30 Days)
- BVFL 112.2K
- PROK 18.2M
- Earning Date
- BVFL 07-17-2025
- PROK 08-08-2025
- Dividend Yield
- BVFL N/A
- PROK N/A
- EPS Growth
- BVFL N/A
- PROK N/A
- EPS
- BVFL 1.06
- PROK N/A
- Revenue
- BVFL $38,257,000.00
- PROK $306,000.00
- Revenue This Year
- BVFL N/A
- PROK $54.34
- Revenue Next Year
- BVFL N/A
- PROK N/A
- P/E Ratio
- BVFL $14.88
- PROK N/A
- Revenue Growth
- BVFL 1.89
- PROK N/A
- 52 Week Low
- BVFL $12.02
- PROK $0.46
- 52 Week High
- BVFL $18.19
- PROK $4.92
- Technical
- Relative Strength Index (RSI)
- BVFL 73.22
- PROK 94.30
- Support Level
- BVFL $15.78
- PROK $0.54
- Resistance Level
- BVFL $15.41
- PROK $0.73
- Average True Range (ATR)
- BVFL 0.39
- PROK 0.51
- MACD
- BVFL 0.17
- PROK 0.51
- Stochastic Oscillator
- BVFL 97.56
- PROK 98.18
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.